Literature DB >> 14684564

Dysbiosis in inflammatory bowel disease.

C P Tamboli1, C Neut, P Desreumaux, J F Colombel.   

Abstract

Abundant data have incriminated intestinal bacteria in the initiation and amplification stages of inflammatory bowel diseases. However, the precise role of intestinal bacteria remains elusive. One theory has suggested a breakdown in the balance between putative species of "protective" versus "harmful" intestinal bacteria--this concept has been termed "dysbiosis". Arguments in support of this concept are discussed.

Entities:  

Mesh：

Year:  2004        PMID： 14684564      PMCID： PMC1773911          DOI： 10.1136/gut.53.1.1

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  61 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 2.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 3.  Microbial factors in inflammatory bowel disease.

Authors:  Richard J Farrell; J Thomas LaMont
Journal:  Gastroenterol Clin North Am       Date:  2002-03       Impact factor: 3.806

4.  Selected bacterial antibodies in Crohn's disease and ulcerative colitis.

Authors:  I O Auer; A Röder; F Wensinck; J P van de Merwe; H Schmidt
Journal:  Scand J Gastroenterol       Date:  1983-03       Impact factor: 2.423

5.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

6.  T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans.

Authors:  R Duchmann; E May; M Heike; P Knolle; M Neurath; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

7.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

8.  Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease.

Authors:  Naohiro Inohara; Yasunori Ogura; Ana Fontalba; Olga Gutierrez; Fernando Pons; Javier Crespo; Koichi Fukase; Seiichi Inamura; Shoichi Kusumoto; Masahito Hashimoto; Simon J Foster; Anthony P Moran; Jose L Fernandez-Luna; Gabriel Nuñez
Journal:  J Biol Chem       Date:  2003-01-04       Impact factor: 5.157

9.  The faecal flora of patients with Crohn's disease.

Authors:  F Wensinck; P A Poppelaars-Kustermans; A M Schröder
Journal:  J Hyg (Lond)       Date:  1981-08

10.  The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.

Authors:  J D Taurog; J A Richardson; J T Croft; W A Simmons; M Zhou; J L Fernández-Sueiro; E Balish; R E Hammer
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307
View more
  232 in total

1.  The role of oral hygiene in inflammatory bowel disease.

Authors:  Shashideep Singhal; Delia Dian; Ali Keshavarzian; Louis Fogg; Jeremy Z Fields; Ashkan Farhadi
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

Review 2.  Functional analysis of colonic bacterial metabolism: relevant to health?

Authors:  Henrike M Hamer; Vicky De Preter; Karen Windey; Kristin Verbeke
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-20       Impact factor: 4.052

Review 3.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

4.  Rifaximin for inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

Review 5.  Role of the gut microbiota in defining human health.

Authors:  Kei E Fujimura; Nicole A Slusher; Michael D Cabana; Susan V Lynch
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

6.  Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet.

Authors:  Mitsuro Chiba; Toru Abe; Hidehiko Tsuda; Takeshi Sugawara; Satoko Tsuda; Haruhiko Tozawa; Katsuhiko Fujiwara; Hideo Imai
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

Review 7.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

9.  PTPN2 controls differentiation of CD4⁺ T cells and limits intestinal inflammation and intestinal dysbiosis.

Authors:  M R Spalinger; S Kasper; C Chassard; T Raselli; I Frey-Wagner; C Gottier; S Lang; K Atrott; S R Vavricka; F Mair; B Becher; C Lacroix; M Fried; G Rogler; M Scharl
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

Review 10.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.